| 48.01 -0.11 (-0.23%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 58.07 | 1-year : | 67.82 |
| Resists | First : | 49.72 | Second : | 58.07 |
| Pivot price | 46.46 |
|||
| Supports | First : | 45.94 |
Second : | 43.61 |
| MAs | MA(5) : | 47.88 |
MA(20) : | 46.85 |
| MA(100) : | 38.26 |
MA(250) : | 0 | |
| MACD | MACD : | 1 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 78.1 |
D(3) : | 77.6 |
| RSI | RSI(14): 60.2 |
|||
| 52-week | High : | 64.63 | Low : | 28.53 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BRKR ] has closed below upper band by 22.2%. Bollinger Bands are 26.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 48.27 - 48.51 | 48.51 - 48.71 |
| Low: | 47.06 - 47.32 | 47.32 - 47.54 |
| Close: | 47.63 - 48.04 | 48.04 - 48.37 |
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Fri, 26 Dec 2025
Why a $30 Million Bruker Stock Trim Matters Amid an 18% Slide - The Globe and Mail
Fri, 26 Dec 2025
Should You Continue to Hold BRKR Stock in Your Portfolio? - TradingView — Track All Markets
Mon, 22 Dec 2025
Why Bruker (BRKR) Stock Is Up Today - Finviz
Mon, 22 Dec 2025
Bruker (BRKR) Stock Up on €35M RI Research Instruments Contract Win | December 2025 - News and Statistics - IndexBox
Mon, 22 Dec 2025
Bruker Corporation $BRKR Shares Sold by Orion Porfolio Solutions LLC - MarketBeat
Sun, 21 Dec 2025
Bruker: Still Not A Healthy Diagnosis - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 152 (M) |
| Shares Float | 103 (M) |
| Held by Insiders | 31.9 (%) |
| Held by Institutions | 90.2 (%) |
| Shares Short | 13,700 (K) |
| Shares Short P.Month | 13,850 (K) |
| EPS | -0.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.05 |
| Profit Margin | -0.7 % |
| Operating Margin | 12.9 % |
| Return on Assets (ttm) | 3.6 % |
| Return on Equity (ttm) | -1.1 % |
| Qtrly Rev. Growth | -0.5 % |
| Gross Profit (p.s.) | 11.05 |
| Sales Per Share | 22.64 |
| EBITDA (p.s.) | 3.85 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 94 (M) |
| Levered Free Cash Flow | 261 (M) |
| PE Ratio | -300.07 |
| PEG Ratio | 0 |
| Price to Book value | 2.98 |
| Price to Sales | 2.12 |
| Price to Cash Flow | 77.35 |
| Dividend | 0.05 |
| Forward Dividend | 0 |
| Dividend Yield | 0.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|